Entry into a Material Definitive Agreement

SEC Filing Summary: Ekso Bionics Holdings, Inc. (8-K)

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Ekso Bionics Holdings, Inc. on February 8, 2021, with the earliest event reported on the same date. The filing details the entry into a material definitive agreement for an underwritten public offering of common stock. The transaction closed on February 11, 2021.

Key Financial Metrics and Transaction Details

  • Shares Issued: 3,902,440 shares of Common Stock.
  • Offering Price: $10.25 per share to the public.
  • Underwriting Price: $9.5325 per share (reflecting a 7.0% underwriting discount).
  • Estimated Net Proceeds: Approximately $36.4 million, or approximately $41.9 million if the underwriter's option is exercised in full.
  • Underwriter Option: H.C. Wainwright & Co., LLC holds a 30-day option to purchase up to 585,366 additional shares.
  • Warrants Issued: 5-year warrants to purchase 273,170 shares (7.0% of shares sold) at an exercise price of $12.8125 per share (125% of the offering price).
  • Additional Costs: The Company agreed to reimburse up to $100,000 for accountable expenses, $50,000 for non-accountable expenses, $15,950 in clearing fees, and a 1.0% management fee on gross proceeds.

Note: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for the Company's operations.

Material Changes

The primary material change is the capital raise through the issuance of new equity and warrants. This transaction increases the Company's cash position by an estimated $36.4 million to $41.9 million and results in the dilution of existing shareholders through the issuance of new shares and warrants.

Outlook, Risks, and Contingencies

The filing does not contain specific forward-looking guidance, management commentary on future operations, or a discussion of risks beyond the standard representations and warranties in the Underwriting Agreement. The warrants and warrant shares are unregistered and issued in reliance on Section 4(a)(2) of the Securities Act and Regulation D.

Key Facts for Investor Verification

  • Verify the final closing date and actual net proceeds received on February 11, 2021.
  • Confirm whether H.C. Wainwright & Co., LLC exercised the option to purchase the additional 585,366 shares within the 30-day window.
  • Review the impact of the new share issuance and warrants on the Company's fully diluted share count and earnings per share.
  • Check subsequent filings for the use of proceeds and any changes in the Company's liquidity position.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.